Living with ulcerative colitis in Germany: A retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Conclusions: These data suggest that control with current biologics is suboptimal. Further treatment options that provide sustained steroid-free remission for this patient population without the need for dose escalations or concomitant therapies may be warranted.
PMID: 31858853 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Databases & Libraries | Economics | Gastroenterology | Germany Health | Health Insurance | Health Management | Healthcare Costs | Humira | Inflammatory Bowel Disease | Insurance | Nutrition | Remicade | Statistics | Study | Ulcerative Colitis